Prostate cancer screening and PSA: the informed decision in AU general practice

Prostate cancer is Australia’s most common male cancer. With around 25,000 new diagnoses each year and a lifetime risk of approximately one in six men, it comes up in general practice constantly — most often as a conversation about whether to test. The challenge is that PSA testing is not a simple screening story: it detects some cancers early enough to make a difference, but also detects many that would never have harmed the man, setting off a cascade of biopsy, treatment, and side effects for no benefit.

The current Australian approach, set out in the 2024 PCFA / Cancer Council Prostate Cancer Testing Guidelines and RACGP Red Book, is shared decision-making — not population screening. The conversation belongs in general practice, where the GP knows the patient’s values, comorbidities, and life expectancy.

A. Core clinical — the AU general practice framework

Who to screen and when

The 2024 guidelines from PCFA and Cancer Council support an informed PSA discussion with:

• Men aged 50–69 — the age group with clearest mortality benefit from the ERSPC trial data
• Men aged 45–69 with a first-degree relative (father or brother) with prostate cancer — elevated risk warrants earlier conversation
• Men aged 40+ with BRCA1 or BRCA2 pathogenic variants — significantly elevated risk; earlier, more intensive monitoring
• ATSI men — lower incidence but higher mortality from later presentation; culturally appropriate discussion is important

Do not screen:

• Men over 70 with life expectancy under ten years — treatment harms outweigh benefit; the cancer is unlikely to determine lifespan
• Men who, after a clear informed discussion, decline testing

The informed consent conversation

Before ordering PSA, the RACGP Red Book recommends documenting a discussion covering:

• Benefits — modest prostate cancer mortality reduction (absolute benefit around 1 fewer cancer death per 1,000 men screened over ten years in ERSPC)
• Harms — over-detection of indolent disease; biopsy complications (infection, haematuria, pain); treatment morbidity (incontinence, erectile dysfunction, bowel symptoms); anxiety
• The mpMRI pathway — elevated PSA now leads to MRI first, not immediate biopsy, which substantially reduces unnecessary procedures
• Patient values — some men strongly want early detection regardless of overtreatment risk; others place more weight on avoiding unnecessary treatment

Document the discussion in the medical record regardless of whether the patient proceeds.

PSA interpretation — key pitfalls

The 5-alpha-reductase inhibitor (5ARI) correction. Men taking finasteride (Proscar, Propecia) or dutasteride (Avodart) for benign prostatic hyperplasia (BPH) or hair loss have their PSA suppressed by approximately 50%. The measured PSA must be doubled before interpreting against standard thresholds. Failure to apply this correction has led to missed diagnoses.

Transient elevations. Defer PSA testing for at least 24–48 hours after ejaculation, digital rectal examination, catheterisation, cystoscopy, or vigorous cycling. Acute prostatitis markedly elevates PSA; allow six to eight weeks post-acute prostatitis before PSA interpretation.

General threshold. A PSA of approximately 3 ng/mL at age 50–70 is the conventional threshold for further investigation, though interpretation is age-contextual and should consider PSA velocity, PSA density, free/total PSA ratio (useful in the 2–10 ng/mL borderline range), and clinical context.

The diagnostic pathway after elevated PSA

Since the PRECISION trial (NEJM 2018) demonstrated that mpMRI before biopsy significantly reduces unnecessary biopsies while improving detection of clinically significant cancers, the Australian pathway has become:

1. Elevated PSA + abnormal DRE → multiparametric MRI prostate (MBS item 63541, Medicare-rebatable since 2018)
2. MRI PI-RADS 1–2 → surveillance; repeat PSA in 12 months
3. MRI PI-RADS 3 → equivocal; shared decision-making; may proceed to biopsy depending on other factors
4. MRI PI-RADS 4–5 → transperineal biopsy (preferred over TRUS biopsy for lower infection risk); urology referral
5. Histology → Gleason grade / ISUP grade + clinical and imaging staging → treatment decision

Digital rectal examination remains part of the assessment — an abnormal DRE (nodule, induration, asymmetry) is an indication for further investigation regardless of PSA level.

B. Evidence appraisal — screening, surveillance, and staging

PSA screening evidence

The ERSPC trial — the largest randomised prostate cancer screening trial — showed a sustained reduction in prostate cancer mortality at sixteen years of follow-up, particularly in the age-appropriate cohort. The US PLCO trial showed equivocal results, partly attributed to high contamination (screening in the control arm). The balance of evidence supports PSA screening as beneficial for appropriate men with adequate counselling, but not for population-wide unconsented screening.

Active surveillance evidence

The ProtecT trial (NEJM 2016) randomised men with low-risk prostate cancer to active surveillance, radical prostatectomy, or radical radiotherapy. At ten-year follow-up: prostate cancer-specific survival was equivalent across all three groups (~98–99%). Metastasis and disease progression were slightly higher with surveillance, but overall mortality was identical. The take-home: for low-risk disease, active surveillance is not inferior to immediate treatment in cancer outcomes, and avoids the certain harms of surgery and radiotherapy.

USANZ and Cancer Council Australia support active surveillance as the preferred approach for ISUP Grade 1 (Gleason 6) disease with PSA under 10 ng/mL, organ-confined on imaging.

PSMA-PET/CT in staging

PSMA-PET/CT (MBS items introduced 2022) is now the standard of care for staging high-risk localised prostate cancer and for investigating biochemical recurrence after treatment. It substantially outperforms conventional bone scan plus CT in sensitivity and specificity, and has changed treatment planning for many men by identifying nodal and metastatic disease missed on prior imaging.

C. Advanced disease and ADT management in general practice

For men with locally advanced or metastatic prostate cancer, androgen deprivation therapy (ADT) is a cornerstone of treatment, but it creates a set of long-term complications that fall squarely in the GP’s domain:

Bone health. ADT causes significant bone loss. DXA scanning and calcium plus vitamin D supplementation are standard. For high fracture risk, bisphosphonate or denosumab therapy (PBS Authority Required for specified indications) is appropriate — discussed with the treating oncologist/urologist.

Cardiovascular risk. ADT increases cardiovascular event risk — metabolic syndrome, dyslipidaemia, hypertension, glucose intolerance. The Heart Health Check (MBS item 699) is relevant for men on ADT. Active optimisation of cardiovascular risk factors is the GP’s role alongside the specialist team.

Mood and mental health. Depression is common on ADT and post-cancer diagnosis. The Mental Health Care Plan enables psychology referral. Screening for depression at every chronic disease review is appropriate.

Sexual function. Discuss with the patient and their partner; sexual health services can provide specialist assessment for penile rehabilitation programs where relevant.

The GPCCMP is appropriate for post-treatment prostate cancer surveillance with multiple comorbidity management targets.

D. Australian operations

MBS pathways

• PSA blood test: item 66655 — Medicare-rebatable
• Multiparametric prostate MRI: item 63541 — Medicare-rebatable since 2018
• PSMA-PET/CT: items from 2022 — for high-risk staging and biochemical recurrence
• DXA for bone density: item 12306
• Heart Health Check: item 699
• GPCCMP: items 965/967

PBS

• ADT (LHRH agonists/antagonists — leuprorelin, goserelin, degarelix) requires PBS Authority for prostate cancer
• Novel hormonal agents (abiraterone, enzalutamide, apalutamide, darolutamide) are Section 100 Authority for advanced disease
• Olaparib requires Authority for BRCA-mutated castration-resistant disease
• Lu-177-PSMA-617 (Pluvicto) requires Authority for PSMA-positive metastatic castration-resistant prostate cancer
• All available via PBS under specialist prescription

E. Special populations

ATSI men. Prostate cancer incidence is lower in Indigenous men overall, but mortality is disproportionately higher from later-stage presentation and less access to specialist care. Culturally safe, proactive discussion about testing during health assessments (MBS item 715) is appropriate for eligible men in the 45–69 age range.

BRCA1/2 carriers. These men have substantially higher lifetime risk and earlier-onset aggressive prostate cancer. Discussion from age 40, genetic counselling for family members, and closer surveillance intervals are appropriate per Cancer Council Australia.

Family history without known BRCA variant. A first- or second-degree relative with prostate cancer, or a family history of breast or ovarian cancer in female relatives, warrants earlier PSA discussion and consideration of genetic testing, particularly in younger men or those with multiple affected relatives.

Men over 70. The benefit-harm balance shifts substantially with age and comorbidity. For most men over 70 with life expectancy under ten years, do not initiate PSA screening. For fit, healthy men over 70 with longer life expectancy, the decision is individual.

When to escalate

Refer urgently to urology or cancer services when:

• Suspected metastatic disease: bone pain, lower limb weakness suggesting cord compression, unexplained weight loss with prior prostate cancer — same-day oncology / ED
• PI-RADS 4–5 on mpMRI — urology referral for biopsy planning
• Elevated PSA with abnormal DRE (nodule, induration) regardless of PSA level
• Biochemical recurrence after definitive treatment — urology and oncology
• Young man with elevated PSA, even if asymptomatic — earlier threshold for referral

What this article is and is not

This is general health information drawn from Australian guidelines — RACGP Red Book, PCFA / Cancer Council 2024 Testing Guidelines, USANZ, and AMH. It does not constitute personal medical advice and does not replace discussion with your own GP and treating clinicians, who understand your individual circumstances and risk profile.

For Australian consumer resources: HealthDirect — Prostate cancer, PCFA, Cancer Council, Healthy Male.

---

Sources cited

1. RACGP Red Book — Prostate cancer
2. PCFA / Cancer Council — 2024 Prostate Cancer Testing Guidelines
3. Cancer Council Australia — Prostate cancer guidelines
4. USANZ
5. Australian Medicines Handbook
6. PBS — ADT, novel hormonal agents, olaparib, Pluvicto listings
7. HealthDirect — Prostate cancer
8. Healthy Male
9. PRECISION trial — MRI before biopsy (NEJM 2018)
10. ProtecT trial — active surveillance vs radical treatment (NEJM 2016)
11. SELECT trial — vitamin E and selenium (JAMA 2011)
12. ERSPC — European randomised screening trial (NEJM, 16-year update)